Abstract: This study examined the presence and cellular localization of three types of opioid receptors (MOR, DOR and KOR) in five human cancer cell lines: MCF-7, MDA-MB-231, HT-29, MGH-U1 and SH-SY5Y. Expression levels of opioid receptors were measured quantitatively using real-time PCR, and the localizations of the receptors in the cells were determined by immunocytochemistry. All three types of opioid receptors were present in each of the five cell lines examined. However, three of the cell lines (MCF-7, HT-29 and SH-SY5Y) showed significantly higher levels of MOR mRNA and protein than the other two types of receptors (DOR and KOR). Immunocytochemistry revealed that MOR, DOR and KOR receptors were predominantly present on the surface of cell membranes, although these receptors were also occasionally present in the cell cytoplasm.
Introduction
Opioid receptors belong to the superfamily of G proteincoupled receptors and couple to various effectors, such as adenylyl cyclase, calcium and potassium channels, via the pertussis toxin-sensitive G i/0 family of G proteins [1] . Pharmacological studies using highly selective ligands have classified opioid receptors into three main types, designated μ, δ and κ or MOR, DOR and KOR, respectively [2] . Molecular cloning studies over the past 15 years have confirmed this classification [3] [4] [5] [6] . Each opioid receptor type has distinct binding properties for various opioid ligands and a distinct localization and distribution within the body [7, 8] .
Opioid receptors and their ligands are mainly found in the central nervous system, although they may also occur in peripheral organs and tissues [7, 9] . Recently, the presence of opioid receptors has been reported in different cancer cells [reviewed in 10] and have been shown to be integral components of a wide variety of human and animal tumor cells, both in neural and non-neural tissues. The tumor types examined in previous studies were of ectodermal, mesodermal and endodermal origin, and some were malignant and others benign.
The occurrence of opioid receptors in tumor cells has prompted experimental studies investigating the effects of opioids on tumor growth in animals as well as the proliferation and survival of cancer cells in vitro. Unfortunately, the results obtained to date are controversial and often inconclusive. The most frequently used opioid in these studies was morphine, an exogenous ligand of MOR receptors. Reports on the effect of morphine in experimental and human cancers are conflicting; both growth-promoting and growthinhibiting effects have been demonstrated [11] [12] [13] . In contrast to exogenous ligands, little is known about the role of endogenous opioid peptides in cancer cells.
However, their influence should not be overlooked as they may have important effects during the earlier stages of a cancer. In order to investigate the influence of different opioids on cancer cells, we must first determine which opioid receptor types are present in these cells.
In this study, we investigated the level of expression and the localization of mRNA and protein of MOR, DOR and KOR receptors in five human cancer cell lines. Our objective was to facilitate the choice of cell lines for further studies on the effects of opioid ligands in cancer cells.
Experimental Procedures

Cell cultures
The following human cancer cell lines were purchased from the European Collection of Cell Cultures (ECACC): two breast cancer cell lines, hormone-independent MCF-7 and hormone-dependent MDA-MB-231, colon cancer HT-29, neuroblastoma SH-SY5Y and bladder cancer MGH-U1.
All cell lines were cultured according to the manufacturer's instructions in culture mediums supplemented with gentamycin (5 µg/ml) and 10% heatinactivated fetal bovine serum (both from Biological Industries, Haemek, Israel). Cells were maintained at 37°C in a 5% CO 2 atmosphere and grown until they were 80% confluent.
Cells from each cell line were seeded in 25 ml culture flasks in standard growth medium at a density of 2.5 x 10 5 cells/flask. After 48 h, they were washed twice with PBS (Invitrogen, Carlsbad, CA, USA) with 0.01 M EDTA (Sigma-Aldrich, St. Louis, MO, USA), and later harvested by trypsinization. Cells used for mRNA isolation were frozen and kept at -80 o C, whereas cells for immunocytochemistry were centrifuged and fixed with phosphate-buffered formaldehyde (Warszawskie Zakłady Farmaceutyczne Polfa, Warsaw, Poland) for 15 min at a pH of 7.4. After centrifugation, the excess formaldehyde was removed and cytological smears were prepared on SuperFrost Plus slides (MenzelGlaser, Braunschweig, Germany). Cytological smears were fixed with 75% ethanol.
Quantitative RT-PCR assay
We used RT-PCR with an ABI Prism 7000 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) to quantify the expression of MOR, DOR and KOR mRNA and protein as well as the expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH), which was used as a house-keeping gene. Total cellular RNA (1 mg) was extracted from the following human cancer cell lines: MCF-7, MDA-MB-231, HT-29, SH-SY5Y and MGH-U1 using Trizol reagent (Invitrogen Life Technologies Inc., Rockville, MD, USA) and a single-step purification protocol [14] . RNA pellets were dissolved in water and their concentration and purity was determined by spectrophotometric readings at 260 and 280 nm. The relative amounts of the specific mRNAs were quantified by RT-PCR.
Extracted RNA was processed directly to cDNA using an Oligotex kit (Qiagen, Chatsworth, CA, USA). The cDNAs were amplified with forward and reverse primers, which are specific for human MOR, DOR, and KOR receptors and GAPDH. Primers were designed using PrimerExpress software (Applied Biosystems, Foster City, CA, USA). MOR primer sequences were 5' GTCCTTTATGCATTTCTGGATGAAAAC 3' (forward) and 5' CTG GAAGCAGAAACTGCTCCGTTG 3' (reverse). DOR primer sequences were 5' GGCTACGCCAATAGCAGCCTCAAC 3' (forward) and 5' CCCGTCCGATGG TCCCGGCGGTTGGCG 3' (reverse). KOR primer sequences were 5' GCTGCTCTCTCCAGCTATTACTTCT 3' (forward) and 5' GAGTCCGAAATACAGTTCAGGATCCTGC 3' (reverse).
GAPDH, the internal control, was amplified using primer sequences 5′-GTCGCTGTTGAAGTCAGAGGAG-3′ (forward) and 5′ CGTGTCAGTGGTGGACCTGAC-3′ (reverse).
To create standard curves, we amplified 125, 100, 75, 50, 25, and 12.5 ng of the obtained cDNAs for GAPDH and for each of the target genes (MOR, DOR and KOR) in triplicate. In the same way, we amplified 100 ng of cDNA for GAPDH, as well as 100 ng of cDNA for each primer/probe combination. 50 μl of each sample containing the respective forward and reverse primers (0.3 μM) were prepared using qPCR TM Mastermix for SYBR Green I (Eurogentec S.A., Liege Science Park, Belgium) and amplified in a separate 96-well plate. All samples were incubated at 50°C for 2 min and at 95°C for 10 min, and then cycled at 95°C for 30 s, 56°C for 1 min, and 72°C for 1 min, for 40 cycles. SYBR Green I fluorescence emissions were captured and mRNA levels were quantified using the critical threshold (C t ) value. Controls without reverse transcription and with no cDNA template were included with each assay. Relative gene expression levels were obtained using the ∆∆C t method [15] . For each determination, three independent experiments were performed in duplicate.
Immunocytochemistry
Cytological smears were put into PBS (Invitrogen, Carlsbad, CA, USA). Endogenous peroxidase activity was blocked by 0.3% hydrogen peroxide in distilled water for 30 min. The smears were rinsed with Tris-buffered saline (TBS, DakoCytomation, Denmark) and incubated overnight with rabbit polyclonal antiopioid receptor antibodies as follows: MOR (ab17934, dilution 1:300), DOR (ab63536, dilution 1:400) and KOR (ab10283, dilution 1:300). All primary antibodies were purchased from Abcam Inc. Cambridge, MA, USA. We used the visualisation system EnVision+System-HRP (DakoCytomation, Denmark) prepared in accordance with the manufacturer's instructions. Visualisation was performed by incubating the smears in a solution of 3,3'-diaminobenzidine (DAB) (DakoCytomation, Denmark). After washing, the smears were counterstained with hematoxylin and covered with a coverslip. For each antibody and for each sample, a negative control was processed. Negative controls were carried out by incubation in the absence of the primary antibody and always yielded negative results. Immunoreactivity was observed under an Olympus BX41 microscope (Olympus Optical Co., Tokyo, Japan).
Results and Discussion
Several cancer cell lines were examined in this study: breast, hormone-dependent MCF-7 and hormoneindependent MDA-MB-231, colon HT-29, bladder MGH-U1 and neuronal SH-SY5Y. We examined the expression of the MOR, DOR, and KOR mRNAs in the cancer cells using the quantitative real-time PCR. Our results demonstrated the presence of all three types of opioid receptor mRNAs in all of the cell lines tested. However, we did observe significant differences in the relative ratios of MOR, DOR and KOR mRNA expression levels among the different cell lines (Figure 1) . In three of the lines (MCF-7, HT-29 and SH-SY5Y), the level of MOR mRNA was higher than the level of DOR and KOR mRNA (0.927±0.031, 0.603±0.032 and 0.532±0.032, respectively). High expression levels of MOR mRNA in SH-SY5Y cells supports data obtained from previous studies [16, 17] . The lowest level of opioid receptor mRNA was observed in MDA-MB231 and MGH-U1 cells. Interestingly, two breast cancer cell lines, hormonedependent MCF-7 and hormone-independent MDA-MB231, varied drastically in the expression of MOR mRNA (0.927±0.031 and 0.035±0.005, respectively).
Among all the cell lines tested, MOR mRNA expression was the highest in MCF-7 cells and was the lowest in MDA-MB231 cells.
We also examined the presence and localization of opioid receptor proteins in the same five cell lines using immunocytochemical analysis. All cells were treated with antibodies against the three types of opioid receptors. The receptor-antibody complexes obtained were then stained with DAB. Positive immunoreactivity was indicated by a brown staining (Figure 2) . If the number of intensely stained cells (out of 100) was below 30%, the reaction was considered weak (+); if it was between 31 and 60%, it was considered medium (++); and above 60%, it was considered strong (+++). The level of protein expression estimated in such way is shown in Table 1 . The highest protein expression levels were observed in MCF-7, HT-29 and SH-SY5Y cells, which was in good agreement with the mRNA results. MOR, DOR and KOR proteins were found in the plasma membrane of all cells examined. These proteins were also found in the cytoplasm of MCF-7, HT-29 and SH-SY5Y cell lines, but the immunoreactivity observed in the membranes was much stronger than in the cytoplasm.
Some authors have shown that opioid receptors may also be found in the nucleus of cells. For instance, the presence of MOR in cell nuclei was reported by Nylund et al. [18] in colon HT-29 cells and by KhorramManesh et al. [19] in human mesothelial Mer-5A cells. In contrast to these results, we did not identify opioid receptors in the nucleus of HT-29 cells. Kivell et al. [17] reported the presence of MOR on the membrane and in the cytoplasm but not in the nucleus of SH-SY5Y cells. Clearly, additional research is required which uses different techniques in order to better understand the cellular distribution of opioid receptors in cancer cells. Opioid receptors mediate the biological effects of opioid compounds on the body, such as the modulation of pain. Several studies have also suggested that opioids can elicit biological effects which appear to be independent of their analgesic properties and may affect the survival or proliferation of cells [reviewed in 11] . Such studies can easily be performed on cancer cell lines. For example, Lin et al. showed that high doses of morphine can induce apoptosis in SH-SY5Y cells through the mitochondrial death pathway [20] . However, Zagon et al. found that a variety of exoand endogenous opioid ligands had no influence on the biology of cancer cells [21] . These contrasting results may be due to the different cell lines used and differences in the study design. Nonetheless, understanding the impact of opioids on cancer cells is extremely important since analogs of endogenous opioids that lack the undesirable side-effects of morphine may become a replacement for this analgesic in the future. Furthermore, measuring the expression levels of opioid receptors in different cell lines will provide valuable information for future experiments.
In conclusion, we demonstrated that all three types of opioid receptors were expressed in the cancer cell lines examined in this study. To the best of our knowledge, such a comparison has not been done before. In MCF-7, HT-29 and SH-SY5Y cell lines, MOR mRNA levels were markedly higher compared with levels of DOR and KOR mRNA. We have also shown the presence of MOR, DOR and KOR immunoreactivities in the membrane but partially also in cytoplasmic localization in these cell lines.
